
Soleno Therapeutics (SLNO) Stock Forecast & Price Target
Soleno Therapeutics (SLNO) Analyst Ratings
Bulls say
Soleno Therapeutics Inc.'s financial outlook appears strong, with a full-year 2026 revenue estimate rising to $462.3 million, reflecting robust sales performance. The company has achieved profitability and anticipates a cash position of approximately $500 million by the end of 2025, following an accelerated share repurchase program. Additionally, the early success of the VYKAT XR product, with expected sales between $189 million to $191 million since its launch, indicates a favorable trajectory, supported by significant market access and increasing prescriber engagement.
Bears say
The financial outlook for Soleno Therapeutics is negatively impacted by several fundamental issues, including potential market access and reimbursement challenges that could hinder the uptake of its product candidate, DCCR. Additionally, concerns regarding earlier-than-expected generic erosion of the DCCR franchise and the company's inability to optimize DCCR's value internationally contribute to a grim financial forecast. The combination of these factors has resulted in a significant 20% decline in the stock over the past month, reflecting investor apprehension regarding the company’s future performance.
This aggregate rating is based on analysts' research of Soleno Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Soleno Therapeutics (SLNO) Analyst Forecast & Price Prediction
Start investing in Soleno Therapeutics (SLNO)
Order type
Buy in
Order amount
Est. shares
0 shares